Introduction
Deep brain stimulation (DBS) can be used to treat essential tremor, Parkinson disease, and a movement disorder called dystonia. Deep brain stimulation is used when drugs aren't able to control symptoms. It works by blocking electrical signals in specific areas of the brain that control movement. Surgery is needed to place a thin metal rod, called an electrode, in the brain.
(When severe movement affects both sides of the body, an electrode may be implanted on each side of the brain.) The electrode is attached to a small device called a neurostimulator, which is placed under the skin below the collar bone. Batteries power the neurostimulator to send electrical signals to the electrode. This policy describes when deep brain stimulation may be considered medically necessary.
Note:
The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered. Another common morbidity associated with PD is the occurrence of motor fluctuations, referred to as an "on and off" phenomena, related to the maximum effectiveness of drugs (ie, "on" state) and the nadir response during drug troughs (ie, "off" state). In addition, levodopa, the most commonly used anti-Parkinson drug, may be associated with disabling drug-induced dyskinesias. Therefore, the optimal pharmacologic treatment of PD may involve a balance between optimal effects on PD symptoms versus the appearance of drug-induced dyskinesias. The effect of DBS on both PD symptoms and druginduced dyskinesias has also been studied.
Primary and Secondary Dystonia
DBS has also been investigated in patients with primary and secondary dystonia, defined as a neurologic movement disorder characterized by involuntary muscle contractions, which force certain parts of the body into abnormal, contorted, and painful movements or postures. 
Neurologic and Psychiatric Disorders
The role of DBS in treatment of other treatment-resistant neurologic and psychiatric disorders, particularly Tourette syndrome, epilepsy, major depressive disorders, and obsessive-compulsive disorder (OCD), is also being investigated. Ablative procedures are irreversible and, though they have been refined, remain controversial treatments for intractable illness. Interest has shifted to neuromodulation through DBS of nodes or targets within neural circuits involved in these disorders. Currently, a variety of target areas are being studied. 
∞

Summary of Evidence
Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1 . 
Clinical Input Received from Physician Specialty Societies and Academic
Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
In response to requests, input was received from 2 academic medical centers and 2 physician specialty societies while this policy was under review in 2014. Iinput supported the use of bilateral deep brain stimulation in patients with medically unresponsive tremor in both limbs.
Practice Guidelines and Position Statements European Academy of Neurology
In 2016, the European Academy of Neurology(EAN) published guidelines on neuromodulation in management of chronic pain. 52 Due to "very low" quality of evidence, the Academy could not recommend deep brain stimulation (DBS) for treatment of neuropathic pain.
American Academy of Neurology
Essential Tremor
The American Academy of Neurology (AAN) published an updated guideline on the treatment of ET (essential tremor) in 2011. 53 This update did not change the conclusions and recommendations of the AAN 2005 practice parameters regarding DBS for ET. 54 The guidelines stated that bilateral DBS of the thalamic nucleus may be used to treat medically refractory limb tremor in both upper limbs (level C, possibly effective), but that there were insufficient data regarding the risk/benefit ratio of bilateral vs unilateral DBS in the treatment of limb tremor.
There was insufficient evidence to make recommendations on the use of thalamic DBS for head or voice tremor (level U, treatment is unproven).
∞
Parkinson Disease
The 
Tardive Syndromes
The 2013 guidelines 57 from AAN on the treatment of tardive syndromes were updated in 2018.
58
The latest guidelines state that "pallidal DBS possibly improves tardive dyskinesia and might be considered as a treatment for intractable tardive dyskinesia (Level C, which indicates that the treatment is possibly effective, based on ≥1 class II study and consistent with ≥2 class III studies).
European Society for the Study of Tourette Syndrome
The European Society for the Study of Tourette Syndrome published guidelines on DBS in 2011. 59 The guidelines state that DBS for Tourette syndrome is still in its infancy and that there are no randomized controlled trials that have included a sufficiently large number of patients.
The Society suggested that DBS should only be used in adult, treatment-resistant, and severely affected patients, and highly recommended that DBS be performed in the context of controlled and double-blind trials including larger and carefully characterized groups of patients.
∞
Canadian Network for Mood and Anxiety Treatments
The Canadian Network for Mood and Anxiety Treatments' 2009 clinical guidelines for management of major depressive disorder in adults found emerging evidence to support DBS as an experimental intervention for patients with treatment-refractory depression. 60 There was no consensus on the most effective target brain region for implantation, although 3 regions have been explored (subcallosal cingulated gyrus, the nucleus accumbens, and the ventral caudate/ventral striatum region).
American Society for Stereotactic and Functional Neurosurgery et al
The American Society for Stereotactic and Functional Neurosurgery and the Congress of Neurological Surgeons published a joint systematic review and guidelines on DBS for obsessivecompulsive disorder (OCD) in 2014. 48 The document concluded that there was a single level I study supporting the use of bilateral STN DBS for medically refractory OCD and a single level II study supporting bilateral nucleus accumbens DBS for medically refractory OCD. It also concluded that the evidence on unilateral DBS was insufficient.
National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has published guidance documents on DBS, as discussed in the following subsections.
Tremor and Dystonia
In The 2011 guidance from NICE indicated there is evidence that DBS is efficacious for refractory chronic pain (excluding headache) is associated with serious risks. 62 However, the procedure is "efficacious in some patients" refractory to other treatments. Patients should be informed that DBS may not control their chronic pain symptoms and that possible risks associated with this procedure include the small risk of death.
Intractable Trigeminal Autonomic Cephalgias
The 2011 guidance from NICE indicated that the evidence on the efficacy of DBS for intractable trigeminal autonomic cephalalgias (eg, cluster headaches) was "limited and inconsistent, and the evidence on safety shows that there were serious but well-known adverse effects."
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Refractory Epilepsy
The 2012 guidance from NICE indicated that the evidence on the efficacy of DBS for refractory epilepsy was limited in both quantity and quality: "The evidence on safety showed that there are serious but well-known adverse effects."
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Parkinson Disease
In 2003, NICE stated that the evidence on the safety and efficacy of DBS for treatment of
Parkinson disease "appears adequate to support the use of the procedure." 65 The guidance noted that DBS should only be offered when Parkinson disease is refractory to best medical treatment. o "L-dopa responsive with clearly defined "on" periods.
Medicare National Coverage
o "Persistent disabling Parkinson's symptoms or drug side effects (eg, dyskinesias, motor fluctuations, or disabling "off" periods) despite optimal medical therapy.
o "Willingness and ability to cooperate during conscious operative procedure, as well as during post-surgical evaluations, adjustments of medications and stimulator settings" DBS is not covered for ET or PD patients with ANY of the following:
 "Non-idiopathic Parkinson's disease or "Parkinson's Plus" syndromes.
 "Cognitive impairment, dementia or depression, which would be worsened by or would interfere with the patient's ability to benefit from DBS. 
Regulatory Status
In 1997, the Activa® Tremor Control System (Medtronic) was cleared for marketing by the U.S. Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The
Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply.
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